Dabur India Ltd Share Price – NSE /  BSE

FMCG, Mid Cap

In a regulatory filing made post market hours yesterday, the FMCG major stated that the quarter ended 31st March 2026 witnessed steady momentum in the domestic India business, underpinned by a stable macroeconomic environment.

This strong domestic performance helped offset challenges in our key international markets particularly Middle East, where heightened geopolitical tensions led to demand disruptions and supply chain constraints.

The India FMCG business witnessed sequential recovery in demand and is likely to record high-single digit growth.

Home & Personal care business sustained its double-digit growth trajectory and is likely to grow in mid teens. In the Healthcare vertical, Dabur Honey, Honitus, Health Juices and Hajmola franchise are expected to report robust double-digit growth.

The company?s food & beverage (F&B) vertical saw a sequential improvement and is expected to register low-single digit growth in the quarter.

In terms of channels, organised trade including modern trade, E-commerce and quick commerce maintained their growth momentum alongside a steady recovery in the General Trade.

In International business, while Middle East business was impacted on account of the US-Israel- Iran conflict, our other key markets like Turkey, Bangladesh and UK performed well and continue to grow in double-digits in constant currency terms. The company expects its international business to record low-single digit growth in INR terms.

Overall, we expect consolidated revenues to grow in mid-single digits with operating profit growing ahead of the topline,? Dabur India said.

Dabur India is one of India's leading FMCG companies. The company manufactures personal care, healthcare and food products.

The scrip had risen 0.47% to end at Rs 417.10 on the BSE on Friday.

Dabur India announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 2 May 2026.

Dabur India will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Powered by Capital Market - Live News

Founded by three women -- Shubhika Jain, her sister Suramya Jain and their mother Sangeeta Jain, RAS Beauty is a Raipur-based digital first, fast growing ?Farm-to-Face? luxury skincare brand with a strong presence in the natural beauty segment. RAS?s key products, which include face elixirs, serums, and moisturisers, are infused with essential oils and naturederived actives. The company has demonstrated strong growth momentum with a 3-year CAGR of around 75% with an ARR of approximately Rs 100 crore and high gross margin.

RAS Beauty is the first investment from Dabur Ventures, which was launched in October 2025 with an intent to acquire stake in high-potential, new-age D2C businesses that demonstrate strong growth potential and are closely aligned with Dabur?s long-term strategic vision. Dabur plans to invest around Rs 60 crore in RAS Beauty.

Dabur India executive director ? group head corporate strategy, Mr. Abhinav Dhall, said: ?We are very impressed with the passion and commitment with which Shubhika Jain and her family have built RAS Beauty always keeping the consumer at the forefront. RAS offers a distinct skincare value proposition at the confluence of nature, science and luxury. We believe that the premium beauty segment will witness strong growth in the coming decade and RAS Beauty is well positioned to capture the emerging opportunity.?

RAS Beauty co-founder and CEO Ms Shubhika Jain said: We have been inspired by Dabur's 141-year legacy of building purpose-led, trusted consumer brands. Dabur has proved that nature, science, and consumer trust can coexist at scale, and that is exactly what we are building at RAS. This investment will enable us to accelerate our omnichannel presence, deepen our R&D capabilities, and invest in brand and team building, all in pursuit of our longer-term goal of making RAS a leading name in Indian luxury skincare, at home and globally, while staying true to our core values.?

Dabur is one of India?s leading FMCG companies, specializing in Ayurveda and natural health care, with an extensive distribution network spanning India and key international markets.

The company reported a 7.3% increase in consolidated net profit to Rs 553.61 crore on a 6.1% rise in revenue from operations to Rs 3,558.65 crore in Q3 FY26 over Q3 FY25.

The counter fell 2.55% to Rs 494.65 on the BSE.

Powered by Capital Market - Live News